IN8BIO, INC.

INAB Nasdaq CIK: 0001740279

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address EMPIRE STATE BUILDING, NEW YORK, NY, 10118
Mailing Address EMPIRE STATE BUILDING, NEW YORK, NY, 10118
Phone (646) 600-6438
Fiscal Year End 1231
EIN 825462585

Recent SEC Filings

Form Type Date Filed Document
DEF 14A Definitive proxy statement March 26, 2026 View on SEC
10-K Annual financial report March 12, 2026 View on SEC
8-K Current report of material events March 12, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) March 2, 2026 View on SEC
8-K Current report of material events February 27, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 17, 2026 View on SEC
8-K Current report of material events February 9, 2026 View on SEC
4 Insider stock transaction report February 6, 2026 View on SEC
4 Insider stock transaction report February 6, 2026 View on SEC
4 Insider stock transaction report February 6, 2026 View on SEC

Annual Reports

10-K March 12, 2026
  • Advancing innovative gamma-delta T cell therapies (INB-100, INB-200) in Phase 1 clinical trials for glioblastoma and solid tumors.
  • Strategic focus on core clinical assets after pipeline prioritization, aiming to maximize success with limited resources.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.